Dramatic reduction in primary endpoint with precision testing in stable patients with suspected CAD - PACE-CME

Dramatic reduction in primary endpoint with precision testing in stable patients with suspected CAD

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Long-term efficacy and safety of intravenous iron in HF
Long-term efficacy and safety of intravenous iron in HF
AHA 2022
Long-term efficacy and safety of intravenous iron in HF
Improved outcomes with rapid uptitration of HF medication after acute HF
Improved outcomes with rapid uptitration of HF medication after acute HF
AHA 2022
Improved outcomes with rapid uptitration of HF medication after acute HF
- Prof. Alexandre Mebazaa, MD, PhD
Head-to-head comparison of two loop diuretics in patients hospitalized with HF
Head-to-head comparison of two loop diuretics in patients hospitalized with HF
AHA 2022
Head-to-head comparison of two loop diuretics in patients hospitalized with HF
- Robert J. Mentz, MD
First-in-human study with CRISPR/Cas9-based gene editing in ATTR amyloid cardiomyopathy
First-in-human study with CRISPR/Cas9-based gene editing in ATTR amyloid cardiomyopathy
AHA 2022
First-in-human study with CRISPR/Cas9-based gene editing in ATTR amyloid cardiomyopathy
- Prof. Julian D. Gillmore, MD, PhD